US EditionThe Phase III study of vedicizumab as the first-line treatment for HER2-expressing urothelial carcinoma achieved the two primary study endpoints of PFS and OS, which will reshape the treatment landscape
Summary by Macau Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Yantai, May 12, 2025 /PRNewswire/ -- On May 12, Rongchang Biopharmaceuticals (stock code: 688331.SH/09995.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
